MELBOURNE, Australia, May 8 /PRNewswire-FirstCall/ -- Prana Biotechnology Limited , a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that Craig W. Ritchie, MD, Chief European Clinical Advisor, will present at the Acumen BioFin/Rodman & Renshaw Fourth Annual Global Healthcare Conference in Monaco on Tuesday, May 15 at 10.25 CET (4:25 a.m. EST and 18.25 Melbourne Time). The Conference will be held on May 14 - 15 at Le Meridien Beach Plaza Hotel at the Sea Club.
During the presentation, Dr. Ritchie will address the current status of Prana's development program. Dr. Ritchie's presentation will be web cast live and a replay will be available following the conclusion. To access the live and encore presentations, visit the Prana web site, www.pranabio.com. The presentation will be archived on the Company site for 30 days.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related neurodegenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.
For further information, please visit our web site at www.pranabio.com. Contacts: Investor Relations Media Relations Kathy Price Ivette Almeida T: 646-284-9430 T: 646-284-9455 E: kprice@hfgcg.com E: ialmeida@hfgcg.com
Prana Biotechnology Ltd.CONTACT: Investor Relations, Kathy Price, +1-646-284-9430,kprice@hfgcg.com, or Media Relations, Ivette Almeida, +1-646-284-9455,ialmeida@hfgcg.com, both for Prana Biotechnology Ltd.
Web site: http://www.pranabio.com/
